Parathyroid carcinoma

Journal of Surgical Oncology

Volumn 89, Issue 3, 2005, Pages 136-142

  Mittendorf, Elizabeth A ^a   McHenry, Christopher R ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

HRPT2; Parathyroid carcinoma; Primary HPT

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CINACALCET; CYCLIN D1; FUROSEMIDE; LOOP DIURETIC AGENT; PARAFIBROMIN; RETINOBLASTOMA PROTEIN; SODIUM CHLORIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME 13; CLINICAL FEATURE; DRUG BIOAVAILABILITY; GENE MUTATION; GENE OVEREXPRESSION; GERM LINE; HISTOPATHOLOGIC SKIN REACTION; HRPT2 GENE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY DISEASE; METASTASIS; ONCOGENE; PARATHYROID CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIPPLE SYNDROME; TUMOR SUPPRESSOR GENE;

CARCINOMA; CYCLIN D1; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 14644430385     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20182     Document Type: Review

References (77)

1. Shane E: Parathyroid carcinoma. J Clin Endocrinol Metab 2001;86:485-493.
2. Cavaco BM, Barros L, Pannett AA, et al.: The hyperparathyroidism-jaw tumor syndrome in a Portugese kindred. Q J Med 2001;94:213-222.
3. Dinnen JS, Greenwood RH, Jones JH, et al.: Parathyroid carcinoma in familial hyperparathyroidism. J Clin Pathol 1977; 30:966-975.
4. Haven CJ, Wong FK, van Dam EW, et al.: A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2000;85:1449-1454.
5. Hobbs MR, Pole AR, Pidwirny GN, et al.: Hyperparathyroidism-jaw tumor syndrome: The HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet 1999;64:518-525.
6. Teh BT, Farnebo F, Twigg S, et al.: Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 1998;83:2114-2120.
7. Wassif WS, Farnebo F, Teh BT, et al.: Genetic studies of a family with hereditary hyperparathryoidism-jaw tumor syndrome. Clin Endocrinol 1999;50:191-196.
8. Wassif WS, Moniz CF, Friedman E, et al.: Familial isolated hyperparathyroidism: A distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 1993;77:1485-1489.
9. Cohn K, Silverman M, Corrado J, et al.: Parathyroid carcinoma: The Lahey Clinic experience. Surgery 1985;98:1095-1110.
10. Hakaim AG, Esselstyn CB: Parathyroid carcinoma: 50-year experience at The Cleveland Clinic Foundation. Cleve Clin J Med 1993;60:331-335.
11. Holmes E, Morton D, Ketcham A: Parathyroid carcinoma: A collective review. Ann Surg 1969;169:631-640.
12. Schantz A, Castleman B: Parathyroid carcinoma: A study of 70 cases. Cancer 1973;31:600-605.
13. Shane E, Bilezikian J: Parathyroid carcinoma: A review of 62 patients. Endocr Rev 1982;3:218-226.
14. Wang C, Gaz R: Natural history of parathyroid carcinoma: Diagnosis, treatment and results. Am J Surg 1985;149:522-527.
15. Hundahl SA, Fleming ID, Fremgen AM, et al.: Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. Cancer 1999;86:538-544.
16. Christmas TH, Chapple CR, Noble JG, et al.: Hyperparathyroid-ism after neck irradiation. Br J Surg 1988;75:873-874.
17. Ireland J, Fleming S, Levison D, et al.: Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck. J Clin Pathol 1985;38:1114-1118.
18. Mashburn MA, Chonkich GD, Chase DR, et al.: Parathyroid carcinoma: Two new cases - Diagnosis, therapy, and treatment. Laryngoscope 1987;97:215-218.
19. Miki H, Sumitomo M, Inoue H, et al.: Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery 1996;120:897-901.
20. McHenry CR, Rosen IB, Walfish PG, et al.: Parathyroid crisis of unusual features in a child. Cancer 1993;71:1923-1927.
21. Streeten EA, Weinstein LS, Norton JA, et al.: Studies in a kindred with parathyroid carcinoma. J Clin Endocrinol Metab 1992;75:362-366.
22. Marx SJ, Simonds WF, Agarwal SK, et al.: Hyperparathyroidism in hereditary syndromes: Special expressions and special managements. J Bone Miner Res 2002;17:N37-N43.
23. Carpten JD, Robbins CM, Villablanca A, et al.: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002;32:676-680.
24. Weinstein LS, Simonds WF: HRPT2, a marker of parathyroid cancer. N Engl J Med 2003;349:1691-1692.
25. Farnebo F, Teh BT, Kytola S, et al.: Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998;83:2627-2630.
26. Heppner C, Kester MB, Agarwal SK, et al.: Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997;16:375-378.
27. Mallya SM, Arnold A: Cyclin D1 in parathyroid disease. Front Biosci 2000;5:D367-D371.
28. Hemmer S, Wasenius VM, Haglund C, et al.: Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Path 2001;158:1355-1362.
29. Hsi ED, Zukerberg LR, Yang WI, et al.: Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study. J Clin Endocrinol Metab 1996;81:1736-1739.
30. Tominaga Y, Tsuzuki T, Uchida K, et al.: Expression of PRAD1/cyclin Dl, retinoblastoma gene products, and Ki-67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney International 1999;55:1375-1383.
31. Vasef MA, Brynes RK, Sturm M, et al.: Expression of cyclin D1 in parathyroid carcinomas, adenomas and hyperplasias: A paraffin immunohistochemical study. Modern Pathology 1999;12:412-416.
32. Shattuck TM, Kim TS, Costa J, et al.: Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol 2003;59:180-189.
33. Cryns VL, Thor A, Xu HJ, et al.: Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994;330:757-761.
34. Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-713.
35. Venkitaraman AR: Chromosome stability, DNA recombination and the BRCA2 tumour suppressor. Curr Opin Cell Biol 2001;13:338-343.
36. Patel KJ, Yu VP, Lee H, et al.: Involvement of BRCA2 in DNA repair. Mol Cell 1998;1:347-357.
37. Sharan SK, Morimatsu M, Albrecht U, et al.: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997;386:804-810.
38. Pearce SH, Trump D, Wooding C, et al.: Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol 1996;45:195-200.
39. Haber D, Harlow E: Tumour-suppressor genes: Evolving definitions in the genomic age. Nat Genet 1997;16:320-322.
40. Cavaco BM, Guerra L, Bradley KJ, et al.: Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J Clin Endocrinol Metab 2004;89:1747-1752.
41. Teh BT, Farnebo F, Kristoffersson U, et al.: Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: Linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 1996;81:4204-4211.
42. Howell VM, Haven CJ, Kahnoski K: HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003;40:657-680.
43. Shattuck TM, Valimaki S, Obara T, et al.: Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003;349:1722-1729.
44. Senior K: Vital gene linked to parathyroid carcinoma. The Lancet Oncology 2003;4:713.
45. Cordeiro AC, Montenegro FL, Kulcsar MA, et al.: Parathyroid carcinoma. Am J Surg 1998;175:52-55.
46. Favia G, Lumachi F, Polistina F, et al.: Parathyroid carcinoma: Sixteen new cases and suggestions for correct management. World J Surg 1998;22:1225-1230.
47. Rosen IB, Young JE, Archibald SD, et al.: Parathyroid cancer: Clinical variations and relationship to autotransplantation. Can J Surg 1994;37:465-469.
48. Wynne AG, van Heerden J, Carney JA, et al.: Parathyroid carcinoma: Clinical and pathological features in 43 patients. Medicine 1992;71:197-205.
49. Heath H 3rd, Hodgson SF, Kennedy MA: Primary hyperparathyroidism: Incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980;302:189-193.
50. Silverberg SJ, Shane E, Jacobs T, et al.: Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990;89:327-334.
51. Silverberg SJ, Shane E, de la Cruz L, et al.: Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989;4:283-291.
52. Koea JB, Shaw JH: Parathyroid cancer: Biology and management. Surg Onc 1999;8:155-165.
53. Clayman GL, Gonzalez HE, El-Naggar A, et al.: Parathyroid carcinoma: Evaluation and interdisciplinary management. Cancer 2004;100:900-905.
54. Obara T, Fujimoto Y: Diagnosis and treatment of patients with parathyroid carcinoma: An update and review. World J Surg 1991;15:738-744.
55. Bondeson L, Sandelin K, Grimelius L: Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Rathol 1993;17:820-829.
56. Levin K, Galante M, Clark O: Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 1987;101:647-660.
57. Johnston LB, Carroll MJ, Britton KE, et al.: The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging. J Clin Endocrinol Metab 1996;81:346-352.
58. Obara T, Okamoto T, Ito Y, et al.: Surgical and medical management of patients with pulmonary metastasis from parathyroid carcinoma. Surgery 1993;114:1040-1048.
59. Vetto JT, Brennan MF, Woodruf J, et al.: Parathyroid carcinoma: Diagnosis and clinical history. Surgery 1993;114:882-892.
60. Sandelin K. Parathyroid carcinoma. Cancer Treat Res 1997;89:183-192.
61. Anderson BJ, Samaan NA, Vassilopoulou-Sellin R, et al.: Parathyroid carcinoma: Features and difficulties in diagnosis and management. Surgery 1983;94:906-915.
62. Golden A, Canary JJ, Kerwin DM: Concurrence of hyperplasia and neoplasia of the parathyroid gland. Am J Med 1965;38:562-578.
63. Grammes CF, Eyerly RC: Hyperparathyroidism and parathyroid carcinoma. South Med J 1980;73:814-816.
64. Barnes BA, Cope O: Cancer of the parathyroid glands. Report of 10 cases with endocrine function. JAMA 1961;171:556-559.
65. O'Donovan DK, Meade HS, McGrath J: Parathyroid carcinoma. Ir J Med Sci 1951;6:241-264.
66. Sieracki JC, Horn RC: Nonfunctional carcinoma of the parathyroid gland. Cancer 1960;13:502-506.
67. Chow E, Tsang RW, Brierley JD, et al.: Parathyroid carcinoma - The Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1998;41:569-572.
68. Bilezikian J: Management of acute hypercalcemia. N Engl J Med 1992;326:1196-1203.
69. Jungst D: Disodium clodronate is effective in management of severe hypercalcemia caused by parathyroid carcinoma. Lancet 1984;2:1043.
70. Trigonis C, Cedermark B, Willems J, et al.: Parathyroid carcinoma - Problems in diagnosis and treatment. Clin Oncol 1984;10:11-19.
71. de Papp AE, Kinder B, LiVolsi V, et al.: Parathyroid carcinoma arising from parathyroid hyperplasia: Autoinfarction following intravenous treatment with pamidronate. Am J Med 1994;97:399-400.
72. 2+ and other ions as extracellular (first) messengers. Physiol Rev 1991;71:371-411.
73. Brown EM, Gamba G, Riccardi D, et al.: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-580.
74. 2+ on parathyroid and kidney cells? Kidney Int 1996;49:1042-1046.
75. Nemeth EF, Steffey ME, Hammerland LG, et al.: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-4045.
76. Collins MT, Skarulis MC, Bilezikian JP, et al.: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83:1083-1088.
77. Shoback DM, Bilezikian JP, Turner SA, et al.: The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-5649.